Embodiments herein generally relate to medication delivery and, more particularly, to wearable medication delivery devices for providing medication to a user experiencing a severe medical event.
Some medical situations require rapid delivery of a medication to a person to avoid death or serious injury. For example, if a person is exposed to a chemical warfare agent, such as sarin gas, the person may require the administration of an antidote such as atropine within a very short period of time. Similarly, for someone having a bee-sting allergy, epinephrine must be administered soon after a bee sting occurs. Other such medical conditions or events that may require urgent attention can include episodes caused by food allergies or epileptic attacks. Often, there is not enough time to transport the afflicted person to a care facility or even to bring a medical professional to the person.
As a result, people required to be in zones in which chemical warfare is a possibility, such as soldiers, and people who are known to have medical conditions such as allergic reactions to substances or events such as bee stings or foods are encouraged to carry self-injector devices that permit the quick delivery of a needed medication. These devices are typically about five inches long, cylindrical, and resemble a large pen or magic marker. The user holds one end of the self-injector on an injection site (e.g., the thigh of a leg) and a predetermined amount of medication is automatically injected. One such device is sold under the trade name EPIPEN.
Use of these devices presents a number of drawbacks, however. The user is required to know both how to operate the device and when to operate the device. Improper operation may result in little or no medication actually injected and improper timing may result in injection occurring too late. Furthermore, the user must be conscious and capable of performing the self-injection. Because some chemical agents and allergic reactions cause seizures, the user may be incapable of performing the self-injection due to seizing before the person even realizes that an attack or allergen exposure has occurred. A need therefore exists for a system and method to deliver antidotes and other medication even if or when a user is incapable of doing so.
In the drawings, like reference characters generally refer to the same parts throughout the different views. In the following description, various embodiments of the present invention are described with reference to the following drawings, in which:
Various embodiments described herein include systems and methods for delivering a medication to a person exposed or subjected to an emergency medical event without requiring intervention or action on the part of the person. The event may be a chemical-weapon attack, bee sting, allergic reaction, epileptic attack, or any other event. In some embodiments, a pod or housing encases a reservoir of medication and a delivery device, such as a hypodermic needle. The housing is held in contact with or in close proximity to a body part of a person, such as the person's thigh, via an adhesive, strap, pouch, or any similar means. Sensors in the housing, such as motion sensors, accelerometers, biosensors, or any other type of sensor, sense a physical attribute of the person, such as the motion and/or biochemistry of the person, and a computer processor (and associated circuitry) monitor information collected by the sensors and determine if the person is experiencing a medical event, such as a seizure or allergic attack, based on the information. The housing may further include an output communications device, such as a loudspeaker, vibration generator, thermal indicator, or electric-shock dispenser, that signals to the person that a seizure or other severe medical condition or events has been detected. An input device on or in the housing, such as a button, may be used or activated by the person in response to the signal if the detected condition or event is a false positive to cancel further action. If the system does not include the button or if the user does not press it in time, the system activates the delivery device and injects the medication into the person.
The first and second portions 202 and 204 may be configured to releasably attach to each other, as shown in
The batteries 208 may be used to provide power to the needle unit 210 and may be AA or AAA cell batteries, watch batteries, rechargeable batteries, or any other type or number of batteries (including a single cell battery). In some embodiments, the batteries 208 also or instead provide power to components within the first portion 202. For example, the first portion 202 may have conducting metal elements that mate with corresponding metal elements in the second portion 204 when the first and second portions 202 and 204 are attached to each other, thereby enabling power from the batteries 208 to be provided to components in the first portion 202. The first portion 202 may also or instead have conducting metal elements that contact the batteries 208 themselves (e.g., directly) to thereby supply power to components therein. In other embodiments, the first portion 202 includes another power supply (e.g., one or more additional batteries).
The first and second portions 202 and 204 may similarly have data or signal connectors that form a data or signal path when the first and second portions 202 and 204 are attached together to thereby permit the transmission of data or signals there between. For example, the first portion 202 may have a connector with pins that mates with a socket on the second portion 204 when the first and second portions 202 and 204 are attached to each other. This data or signal path may be used to, for example, communicate between a processor disposed in the first portion 202 and the needle unit 210 in the second portion 204.
The needle unit 210 may include a fluid reservoir for storing and/or dispensing a quantity of liquid medication or drug. In some embodiments, the fluid reservoir can be a cylinder or similar shape having a cross-sectional shape of a circle, oval, rectangle, square, or any other shape. In these embodiments, the needle 212 can be fluidly connected to one end of the cylinder, and a plunger can be disposed at the other end of the cylinder. The medicine or drug may be dispensed through the needle 212 via mechanical or electro-mechanical means, such as an electric motor that turns a gear that advances the plunger. The plunger may alternatively be driven by electrochemical means, such as by causing the creation or expansion of a gas by applying an electric current to a substance to thereby exert a force on the plunger. In other embodiments, the fluid reservoir can exert a force on the liquid medicine disposed therein. For example, one or more inner walls of the fluid reservoir may include an elastic member that is stretched such that it exerts a force on the liquid (e.g., an elastic bladder). A propellant may alternatively be added to the fluid reservoir to exert force on the liquid. In these embodiments, instead of or in addition to a plunger, the needle unit 210 can include a valve that, once open, permits the liquid under pressure to exit the fluid reservoir and travel through the needle 212.
The keys 408 may be moved to thereby release the needle driver 402 and allow the spring 404 to move it, thereby propelling a needle 414 attached to the needle driver 402 forward in response to a signal. Additional support members may be included to guide the needle driver 402 and/or keys 408 such that they move only in one dimension or direction (or otherwise restrict the movement of the needle driver 402 and/or keys 408). As explained in greater detail below, an actuation signal may be generated by a processor that, in response to data collected by a sensor (such as a motion sensor or biosensor), determines that the person wearing the device is experiencing a medical event such as a seizure or allergic attack. In various embodiments, an electrically deformable material 416, such as shape-memory wire made from, for example, copper-aluminum-nickel or nickel-titanium alloys, can be disposed around the needle driver 402 and through holes 418 in the one or more keys 408. Any other type of electrically deformable material, such as magnetic-shape memory, piezoelectric materials, or shape-memory polymer, is within the scope of the present invention. When the signal to release the keys 408 is received, an electric current can be provided to run through electrically deformable material 416, thereby causing it to change shape. For example, the diameter of the electrically deformable material 416 may increase when the current is applied, thereby causing the keys 408 to move away from the needle driver 402 such that the protrusions 410 no longer mate with the notches 412. In other embodiments, the electrically deformable material 416 may be configured to decrease in length when current is applied. In these embodiments, the electrically deformable material 416 can be positioned to pull the keys 408 away from the needle driver 402 to thereby release it. Any configuration of electrically deformable material and keys is within the scope of the present invention as will be understood by one of skill in the art. Further, any other system and method of mechanically actuating a needle to extend into the body of the person in response to a received electric or electronic signal is similarly within the scope of the present invention.
A computer processor 510 may execute software instructions stored in a memory 512. The processor 510 may be, for example, a general-purpose processor, a digital-signal processor, an application specific integrated circuit (ASIC), or any other type of digital logic. The processor 510 may also or instead include analog or mixed-signal circuitry that does not require the execution of software instructions to carry out the methods described herein. The memory 512 may volatile or non-volatile and may be a random access memory (RAM), read only memory (ROM), flash memory, solid-state storage, and/or magnetic storage. The software instructions may include assembly code written directly or compiled from a higher-level language, such as C or JAVA. The computer processor 510 can be considered to be a controller for directing operations and functionality of the medication delivery device 500 overall and the constituent components thereof.
A movement sensor 514 detects movement of the housing 502 and, by extension, movement of the person to whom the housing 502 is attached. Any type of movement sensor is within the scope of the present invention, and the movement sensor 514 may detect position, velocity, acceleration, jerk, orientation, rotation, or any other similar movement type. In some embodiments, the movement sensor 514 can include three microelectromechanical systems (MEMS) capacitors oriented to capture acceleration information on x, y, and z axes. The movement sensor 514 can be in electrical communication with the processor 510 via, for example, wires or a bus. The processor 510, memory 512, and the movement sensor 514 are depicted as separate components but are not so limited. The present invention is not limited to only this arrangement of components as two or more of these components may be combined, such as in a system-on-a-chip arrangement.
A power supply 516 supplies power to the processor 510, memory 512, movement sensor 514, and/or any other components in or on the housing 502 that require power. As mentioned above, the power supply 516 may include one or more cells or batteries, which may be single-use or rechargeable. The power supply 516 may be configured to supply power to the system 500 for a certain minimum amount of time, e.g., one day, two days, or three days. The adhesive 508 may be configured or selected such that it loses some or all of its adhesive properties before this minimum power-supply time, thus prompting the person to replace the system 500 with a new one.
As mentioned above, the processor 510 can determine whether the person is having a seizure by monitoring data received from the movement sensor 514. Any method of seizure detection is within the scope of the present invention. In some embodiments, the processor 510 executes software instructions that calculate the direction, velocity, duration, and/or frequency of the person's movements and compares these factors against thresholds. If the factors exceed one or more thresholds, the processor 510 determines that the person is having a seizure or experience some other serious medical event and sends a signal to a needle actuator 518 to deploy the needle 504 and dispense the medication in the reservoir 506. In some embodiments, for example, if the processor 510 detects a certain number of rapid, back-and-forth movements made by the person within a certain period of time, the processor can determine that the person is having a seizure. The processor 510 may further detect if the person falls to the ground before, during, or after the back-and-forth movements as further evidence of a seizure.
The housing may further include devices for the input of information, such as a button 520, or the output of information, such as speaker/vibrator 522. In some embodiments, if the processor 510 detects a seizure, before signaling the needle actuator 518 to activate, the processor can determine to alert the person using the output device 522 by sounding an alarm and/or causing vibrations. In other embodiments, the output device 522 delivers heat or an electric shock to the body of the person to thereby alert the person. If the person is not having a seizure and presses the button 520 within a certain amount of time (e.g., ten seconds), the processor 510 can cancel deployment of the needle 504. In such instances, the button 520 can operate as an override or false alarm input. In some embodiments, the processor 510 adjusts one or more thresholds in response to the pressing of the button to thereby reduce or prevent false positives in the future.
The needle actuator 518 may represent the system 400 or 450 described above with reference to
Embodiments of the present invention are not limited to only the above-described components as other components and features are within its scope. For example, a network interface 524 may be used to communicate between the system 500 and other systems, such as remote computing devices, servers, or cellular phones. For example, a remote system may transmit a message to the device 500 via any wired or wireless networking protocol, such as WI-FI, ETHERNET, BLUETOOTH, NFC, GSM/CDMA or other cellular networks/standards, that is received using the network interface 524. The message may cause the processor 510 to automatically deploy the needle 504 and medication, cause an output device 522 to beep or vibrate, disable the device 500, or perform any other action.
An environment sensor 526 may be used instead of or in addition to the movement sensor 514. The environment sensor 526 may sample air, water, particles, or other characteristics in a surrounding environment of the device 500 for potentially harmful substances, such as sarin gas. If the environment sensor 526 detects such a substance, it sends a signal to the processor 510, which may deploy the needle 504 in response as described above.
The medication delivery device 500 may also include one or more medical condition sensors (not shown in
The output device 522 can provide a visual or audible alarm to a user. For example, the output device 522 can include one or more visual device—e.g., light emitting diodes (LEDs)—for indicating an alarm. Under such a scenario, the output device 522 can flash one or more LEDs to indicate an alarm and/or can indicate an alarm by a particular color provided by one or more LEDs. The output device 522 can also include a speaker for providing an audible alarm. Further, the output device 522 can include a vibrator for vibrator all or a portion of the medication delivery device 500. As the medication delivery device 500 is directly in physical contact with a user, a vibrational alarm can be quickly detected by the user in a discrete manner. The output device 522 can be or include other components for providing an alarm including, for example, thermal actuator or electrical stimulator.
The reservoir 506 can contain one or more medications or drugs stored in one or more reservoir chambers such that the medication delivery device 500 can respond to one or more different medical events that can be experienced by a user. In various embodiments, the reservoir 506 can store is firazyr, icatibant, epinephrine, atropine, biperiden, and/or pralidoxime. In various embodiments, the medication delivery device 500 can determine a user is experiencing a severe medical event such as exposure to a chemical warfare weapon (e.g., a gas or other toxin), a seizure, an allergic reaction, and an epileptic attack (with any such condition or event caused by exposure to one or more conditions of an environment occupied by the user).
In various embodiments, the medication delivery device 500 can use one or more sensors (e.g., the sensors 514 and/or sensors 526) to sense or detect a physical attribute of a person (e.g., a motion of a user and/or a medical condition such as heart rate of a user) and/or a condition of an environment occupied by a user (e.g., a temperature of the environment and/or the presence of a chemical warfare weapon or gas or other toxin). A controller of the medication delivery device 500 (e.g., the processor 510) can use information collected and provided by the one or more sensors to determine if the user is experiencing a severe medical event. If so, the controller can direct or cause a medication to be automatically delivered to a user (e.g., by way of the needle actuator 518 in conjunction with the needle 504 and reservoir 506). The delivery of the responsive medication is intended to offset the medical event being experienced by the user. Further, the medication is provided automatically such that a user need not actively take steps to ensure delivery of the medication (e.g., to ensure delivery of the medication in situations where the user is unable or incapable of physically manipulating a medication delivery system).
Once a determination is made by the controller that a user is experiencing a medical event, the controller can provide an alarm as discussed above to the user. Within a predetermined amount of time after the determination is made and/or the alarm is provided, the controller can cause or direct the needle actuator 518 to inject the user. The predetermined amount of time (e.g., the wait time or delay time) can vary for different determined medical conditions and/or determined severity of any particular medical event. During this delay or wait time, a user can press a button 520 or other input device to cancel or prevent the automatic injection of the user. If no input is received by the medication delivery device 500 during the delay time, then injection of the user can occur at the end of the predetermined amount of time.
If a user overrides automatic injection and delivery of the medication (e.g., for a false alarm event), then the controller 510 can adjust one or more thresholds associated with detection and determination of medical events. That is, a relatively higher threshold can be required for medical events in order to trigger the automatic response. These higher thresholds could include more motion, more severe motion, more jerky motion, higher levels of detected toxins, and/or higher medical condition readings (e.g., higher heart rates, higher blood pressure) which would need to be met or exceeded before determining any subsequent medical event after false alarm reporting by the user. In essence, thresholds associated with determining instances of a medical event based on information collected by the sensors can be adjusted in response to a false reporting by a user (e.g., so as to reduce the likelihood of a false alarm event in the future). In various embodiments, any override by the user can itself be overridden based on a signal received remotely over the network interface 524. For example, an accidental cancellation of an automatic injection of the user can be overridden by remote observation and direction provide through the network interface 524.
Each of the components shown in the medication delivery device 500 can be physically and/or electrically coupled together. For example, the controller 510 can be coupled electrically to the sensors 514 and 526, the network interface 524, the button 520, the output device 522, the memory 512, and the needle actuator 518 to enable communication and/or control information, signals, and instructions to be provided therebetween. Further, the needle actuator 518 can be physically coupled to the needle 504 and the reservoir 506.
Certain embodiments of the present invention were described above. It is, however, expressly noted that the present invention is not limited to those embodiments, but rather the intention is that additions and modifications to what was expressly described herein are also included within the scope of the invention. Moreover, it is to be understood that the features of the various embodiments described herein were not mutually exclusive and can exist in various combinations and permutations, even if such combinations or permutations were not made express herein, without departing from the spirit and scope of the invention. In fact, variations, modifications, and other implementations of what was described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention. As such, the invention is not to be defined only by the preceding illustrative description.
This application is a Continuation of U.S. patent application Ser. No. 15/358,945, filed on Nov. 22, 2016, which claims priority to U.S. Provisional Patent Application No. 62/259,706, filed on Nov. 25, 2015, the entire contents of both are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
303013 | Horton | Aug 1884 | A |
306691 | Johnson | Oct 1884 | A |
315727 | Church | Apr 1885 | A |
405524 | Benton | Jun 1889 | A |
410817 | Weeks, Jr. | Sep 1889 | A |
2667986 | Perelson | Feb 1954 | A |
3792703 | Moorehead | Feb 1974 | A |
3812843 | Wootten et al. | May 1974 | A |
3841328 | Jensen | Oct 1974 | A |
3885662 | Schaefer | May 1975 | A |
4067000 | Carlson | Jan 1978 | A |
4151845 | Clemens | May 1979 | A |
4152098 | Moody et al. | May 1979 | A |
4193397 | Tucker et al. | Mar 1980 | A |
4211998 | Junginger et al. | Jul 1980 | A |
4231019 | Junginger et al. | Oct 1980 | A |
4261388 | Shelton | Apr 1981 | A |
4268150 | Chen | May 1981 | A |
4276170 | Vaillancourt | Jun 1981 | A |
4342311 | Whitney et al. | Aug 1982 | A |
4346385 | Schiavone et al. | Aug 1982 | A |
4364385 | Lossef | Dec 1982 | A |
4424720 | Bucchianeri | Jan 1984 | A |
4435173 | Siposs et al. | Mar 1984 | A |
4469481 | Kobayashi | Sep 1984 | A |
4475901 | Kraegen et al. | Oct 1984 | A |
4498843 | Schneider et al. | Feb 1985 | A |
4507115 | Kambara et al. | Mar 1985 | A |
4514732 | Hayes, Jr. | Apr 1985 | A |
4529401 | Leslie et al. | Jul 1985 | A |
4551134 | Slavik et al. | Nov 1985 | A |
4559033 | Stephen et al. | Dec 1985 | A |
4559037 | Franetzki et al. | Dec 1985 | A |
4560979 | Rosskopf | Dec 1985 | A |
4562751 | Nason et al. | Jan 1986 | A |
4585439 | Michel | Apr 1986 | A |
4601707 | Albisser et al. | Jul 1986 | A |
4624661 | Arimond | Nov 1986 | A |
4634427 | Hannula et al. | Jan 1987 | A |
4678408 | Nason et al. | Jul 1987 | A |
4684368 | Kenyon | Aug 1987 | A |
4685903 | Cable et al. | Aug 1987 | A |
4734092 | Millerd | Mar 1988 | A |
4743243 | Vaillancourt | May 1988 | A |
4755173 | Konopka et al. | Jul 1988 | A |
4781688 | Thoma et al. | Nov 1988 | A |
4781693 | Martinez et al. | Nov 1988 | A |
4801957 | Vandemoere | Jan 1989 | A |
4808161 | Kamen | Feb 1989 | A |
4836752 | Burkett | Jun 1989 | A |
4855746 | Stacy | Aug 1989 | A |
4858619 | Toth | Aug 1989 | A |
4871351 | Feingold | Oct 1989 | A |
4882600 | Van de Moere | Nov 1989 | A |
4886499 | Cirelli et al. | Dec 1989 | A |
4898578 | Rubalcaba, Jr. | Feb 1990 | A |
4898579 | Groshong et al. | Feb 1990 | A |
4944659 | Labbe et al. | Jul 1990 | A |
4969874 | Michel et al. | Nov 1990 | A |
4973998 | Gates | Nov 1990 | A |
4985016 | Theeuwes et al. | Jan 1991 | A |
5007458 | Marcus et al. | Apr 1991 | A |
5045871 | Reinholdson | Sep 1991 | A |
5062841 | Siegel | Nov 1991 | A |
5109850 | Blanco et al. | May 1992 | A |
5125415 | Bell | Jun 1992 | A |
5176662 | Bartholomew et al. | Jan 1993 | A |
5178609 | Ishikawa | Jan 1993 | A |
5189609 | Tivig et al. | Feb 1993 | A |
5205819 | Ross et al. | Apr 1993 | A |
5213483 | Flaherty et al. | May 1993 | A |
5232439 | Campbell et al. | Aug 1993 | A |
5239326 | Takai | Aug 1993 | A |
5244463 | Cordner, Jr. et al. | Sep 1993 | A |
5245447 | Stemmle | Sep 1993 | A |
5254096 | Rondelet et al. | Oct 1993 | A |
5257980 | Van Antwerp et al. | Nov 1993 | A |
5261884 | Stern et al. | Nov 1993 | A |
5281202 | Weber et al. | Jan 1994 | A |
5308335 | Ross et al. | May 1994 | A |
5312337 | Flaherty et al. | May 1994 | A |
5318540 | Athayde et al. | Jun 1994 | A |
5342313 | Campbell et al. | Aug 1994 | A |
5346476 | Elson | Sep 1994 | A |
5364342 | Beuchat et al. | Nov 1994 | A |
5411480 | Kriesel | May 1995 | A |
5433710 | VanAntwerp et al. | Jul 1995 | A |
5452033 | Balling et al. | Sep 1995 | A |
5492534 | Athayde et al. | Feb 1996 | A |
5503628 | Fetters et al. | Apr 1996 | A |
5507288 | Bocker et al. | Apr 1996 | A |
5514096 | Hiejima | May 1996 | A |
5533389 | Kamen et al. | Jul 1996 | A |
5545152 | Funderburk et al. | Aug 1996 | A |
5573342 | Patalano | Nov 1996 | A |
5575770 | Melsky et al. | Nov 1996 | A |
5576781 | Deleeuw | Nov 1996 | A |
5582593 | Hultman | Dec 1996 | A |
5613956 | Patterson et al. | Mar 1997 | A |
5630710 | Tune et al. | May 1997 | A |
5637095 | Nason et al. | Jun 1997 | A |
5643213 | McPhee | Jul 1997 | A |
5647853 | Feldmann et al. | Jul 1997 | A |
5665065 | Colman et al. | Sep 1997 | A |
5665070 | McPhee | Sep 1997 | A |
5678539 | Schubert et al. | Oct 1997 | A |
5685859 | Kornerup | Nov 1997 | A |
5693018 | Kriesel et al. | Dec 1997 | A |
5695490 | Flaherty et al. | Dec 1997 | A |
5702363 | Flaherty | Dec 1997 | A |
5704520 | Gross | Jan 1998 | A |
5716343 | Kriesel et al. | Feb 1998 | A |
5726404 | Brody | Mar 1998 | A |
5726751 | Altendorf et al. | Mar 1998 | A |
5747350 | Sattler | May 1998 | A |
5748827 | Holl et al. | May 1998 | A |
5755682 | Knudson et al. | May 1998 | A |
5764159 | Neftel | Jun 1998 | A |
5776103 | Kriesel et al. | Jul 1998 | A |
5779676 | Kriesel et al. | Jul 1998 | A |
5785681 | Indravudh | Jul 1998 | A |
5785688 | Joshi et al. | Jul 1998 | A |
5797881 | Gadot | Aug 1998 | A |
5800397 | Wilson et al. | Sep 1998 | A |
5800405 | McPhee | Sep 1998 | A |
5800420 | Gross et al. | Sep 1998 | A |
5810015 | Flaherty | Sep 1998 | A |
5814020 | Gross | Sep 1998 | A |
5840063 | Flaherty | Nov 1998 | A |
5845218 | Altschul | Dec 1998 | A |
5848990 | Cirelli et al. | Dec 1998 | A |
5848991 | Gross et al. | Dec 1998 | A |
5858005 | Kriesel | Jan 1999 | A |
5858239 | Kenley et al. | Jan 1999 | A |
5865806 | Howell | Feb 1999 | A |
5875393 | Altschul et al. | Feb 1999 | A |
5885808 | Spooner et al. | Mar 1999 | A |
5886647 | Badger et al. | Mar 1999 | A |
5891097 | Saito et al. | Apr 1999 | A |
5897530 | Jackson | Apr 1999 | A |
5906597 | McPhee | May 1999 | A |
5911716 | Rake et al. | Jun 1999 | A |
5919167 | Mulhauser et al. | Jul 1999 | A |
5921419 | Niedospial, Jr. et al. | Jul 1999 | A |
5931814 | Alex et al. | Aug 1999 | A |
5935099 | Peterson et al. | Aug 1999 | A |
5954058 | Flaherty | Sep 1999 | A |
5954694 | Sunseri | Sep 1999 | A |
5957890 | Mann et al. | Sep 1999 | A |
5957895 | Sage et al. | Sep 1999 | A |
5961492 | Kriesel et al. | Oct 1999 | A |
5965848 | Altschul et al. | Oct 1999 | A |
5983094 | Altschul et al. | Nov 1999 | A |
5993423 | Choi | Nov 1999 | A |
5997501 | Gross et al. | Dec 1999 | A |
6019747 | McPhee | Feb 2000 | A |
6024539 | Blomquist | Feb 2000 | A |
6050978 | Orr et al. | Apr 2000 | A |
6071292 | Makower et al. | Jun 2000 | A |
6090080 | Jost et al. | Jul 2000 | A |
6126637 | Kriesel et al. | Oct 2000 | A |
6144847 | Altschul et al. | Nov 2000 | A |
6152898 | Olsen | Nov 2000 | A |
6174300 | Kriesel et al. | Jan 2001 | B1 |
6190359 | Heruth | Feb 2001 | B1 |
6200338 | Solomon et al. | Mar 2001 | B1 |
6206850 | ONeil | Mar 2001 | B1 |
6244776 | Wiley | Jun 2001 | B1 |
6309370 | Haim et al. | Oct 2001 | B1 |
6363609 | Pickren | Apr 2002 | B1 |
6375638 | Nason et al. | Apr 2002 | B2 |
6520936 | Mann | Feb 2003 | B1 |
6527744 | Kriesel et al. | Mar 2003 | B1 |
6572585 | Choi | Jun 2003 | B2 |
6666852 | Niedospial, Jr. | Dec 2003 | B2 |
6699221 | Vaillancourt | Mar 2004 | B2 |
6740059 | Flaherty | May 2004 | B2 |
6883778 | Newton et al. | Apr 2005 | B1 |
7018360 | Flaherty et al. | Mar 2006 | B2 |
7025744 | Utterberg et al. | Apr 2006 | B2 |
7060059 | Keith et al. | Jun 2006 | B2 |
7128727 | Flaherty et al. | Oct 2006 | B2 |
7144384 | Gorman et al. | Dec 2006 | B2 |
7160272 | Eyal et al. | Jan 2007 | B1 |
7267665 | Steil et al. | Sep 2007 | B2 |
7291133 | Kindler et al. | Nov 2007 | B1 |
7303549 | Flaherty et al. | Dec 2007 | B2 |
7918825 | OConnor et al. | Apr 2011 | B2 |
9402950 | Dilanni et al. | Aug 2016 | B2 |
20010053895 | Vaillancourt | Dec 2001 | A1 |
20020010423 | Gross et al. | Jan 2002 | A1 |
20020032374 | Holker et al. | Mar 2002 | A1 |
20020066715 | Niedospial | Jun 2002 | A1 |
20030163097 | Fleury et al. | Aug 2003 | A1 |
20040010207 | Flaherty | Jan 2004 | A1 |
20040064088 | Gorman et al. | Apr 2004 | A1 |
20040088224 | Mukai | May 2004 | A1 |
20040092865 | Flaherty et al. | May 2004 | A1 |
20040116847 | Wall | Jun 2004 | A1 |
20040158208 | Hiejima | Aug 2004 | A1 |
20040203357 | Nassimi | Oct 2004 | A1 |
20050187524 | Willis et al. | Aug 2005 | A1 |
20050238507 | Dilanni et al. | Oct 2005 | A1 |
20050258581 | Tanaka | Nov 2005 | A1 |
20060134323 | OBrien | Jun 2006 | A1 |
20060155210 | Beckman et al. | Jul 2006 | A1 |
20060178633 | Garibotto et al. | Aug 2006 | A1 |
20060253085 | Geismar et al. | Nov 2006 | A1 |
20060282290 | Flaherty et al. | Dec 2006 | A1 |
20070005018 | Tekbuchava | Jan 2007 | A1 |
20070025811 | Wilhelm | Feb 2007 | A1 |
20070112332 | Harding et al. | May 2007 | A1 |
20070118405 | Campbell et al. | May 2007 | A1 |
20070173974 | Lin | Jul 2007 | A1 |
20070197163 | Robertson | Aug 2007 | A1 |
20070282269 | Carter et al. | Dec 2007 | A1 |
20080004515 | Jennewine | Jan 2008 | A1 |
20080051738 | Griffin | Feb 2008 | A1 |
20080065000 | Bidinger et al. | Mar 2008 | A1 |
20080078400 | Martens et al. | Apr 2008 | A1 |
20080132880 | Buchman | Jun 2008 | A1 |
20080249508 | Lopez et al. | Oct 2008 | A1 |
20080287906 | Burkholz et al. | Nov 2008 | A1 |
20090054866 | Teisen-Simony et al. | Feb 2009 | A1 |
20090062767 | Van Antwerp et al. | Mar 2009 | A1 |
20090124979 | Raymond et al. | May 2009 | A1 |
20090198215 | Chong et al. | Aug 2009 | A1 |
20090299300 | Truitt et al. | Dec 2009 | A1 |
20100137784 | Cefai et al. | Jun 2010 | A1 |
20100152658 | Hanson et al. | Jun 2010 | A1 |
20110054390 | Searle et al. | Mar 2011 | A1 |
20110054399 | Chong et al. | Mar 2011 | A1 |
20110166512 | Both et al. | Jul 2011 | A1 |
20110230833 | Landman et al. | Sep 2011 | A1 |
20110316562 | Cefai et al. | Dec 2011 | A1 |
20120003093 | Lischer et al. | Jan 2012 | A1 |
20120003935 | Lydon et al. | Jan 2012 | A1 |
20120010594 | Holt | Jan 2012 | A1 |
20120078161 | Masterson et al. | Mar 2012 | A1 |
20120238851 | Kamen et al. | Sep 2012 | A1 |
20120277668 | Chawla | Nov 2012 | A1 |
20130317753 | Kamen et al. | Nov 2013 | A1 |
20140074033 | Sonderegger et al. | Mar 2014 | A1 |
20140127048 | Dilanni et al. | May 2014 | A1 |
20140128839 | Dilanni et al. | May 2014 | A1 |
20140135880 | Baumgartner et al. | May 2014 | A1 |
20160015891 | Papiorek | Jan 2016 | A1 |
20160038689 | Lee et al. | Feb 2016 | A1 |
20160302054 | Kimura et al. | Oct 2016 | A1 |
20170128664 | Diianni et al. | May 2017 | A1 |
Number | Date | Country |
---|---|---|
4200595 | Jul 1993 | DE |
19723648 | Aug 1998 | DE |
19920896 | Nov 2000 | DE |
342947 | Nov 1989 | EP |
0763369 | Mar 1997 | EP |
0867196 | Sep 1998 | EP |
0937475 | Aug 1999 | EP |
2397181 | Dec 2011 | EP |
2830499 | Feb 2015 | EP |
875034 | Aug 1961 | GB |
2443261 | Apr 2008 | GB |
200740148 | Oct 2007 | TW |
8101658 | Jun 1981 | WO |
8606796 | Nov 1986 | WO |
9801071 | Jan 1998 | WO |
9856293 | Dec 1998 | WO |
9910040 | Mar 1999 | WO |
9956803 | Nov 1999 | WO |
9962576 | Dec 1999 | WO |
0019887 | Apr 2000 | WO |
0029047 | May 2000 | WO |
0029049 | May 2000 | WO |
0030705 | Jun 2000 | WO |
0061215 | Oct 2000 | WO |
0074752 | Dec 2000 | WO |
0078210 | Dec 2000 | WO |
0152727 | Jul 2001 | WO |
0156633 | Aug 2001 | WO |
0176684 | Oct 2001 | WO |
0220073 | Mar 2002 | WO |
0226282 | Apr 2002 | WO |
0240083 | May 2002 | WO |
2002068823 | Sep 2002 | WO |
03090509 | Nov 2003 | WO |
2008133702 | Nov 2008 | WO |
2009098648 | Aug 2009 | WO |
2012134589 | Oct 2012 | WO |
2013134486 | Sep 2013 | WO |
2013149186 | Oct 2013 | WO |
Entry |
---|
International Preliminary Report on Patentability for the International Patent Application No. PCT/US2018/018901, dated Sep. 6, 2019, 8 pages. |
International Search Report and Written Opinion for application No. PCT/US2017/015601, dated May 16, 2017, 12 pages. |
International Preliminary Report on Patentability dated Oct. 9, 2014, issued in PCT Patent Application No. PCT/US2013/034674, 15 pages. |
EPO Search Report dated Nov. 11, 2015, received in corresponding Application No. 13768938.6, 7 pgs. |
European Patent Office, “Notification of Transmittal of the ISR and the Written Opinion of the International Searching Authority, or the Declaration,” in PCT Application No. PCT/GB2015/050248, dated Jun. 23, 2015, 12 pages. |
International Preliminary Report on Patentability dated Apr. 9, 2020, issued in PCT Patent Application No. PCT/US2018/052464, 7 pages. |
International Search Report for the International Patent Application No. PCT/US03/16640, dated Oct. 3, 2003, 1 page. |
User's Guide for Model 508 Insulin Pump, Mini Med, 8/00, 145 pages. |
Web-Site Brochure dated Jan. 4, 2000. SOOIL-Homepage. “Portable Insulin Pump”. www.sooil.com/product2.htm. |
Web-Site Brochure dated Jan. 4, 2000. SOOIL-Homepage. ““Portable Insulin Pump””.www.sooil.com/product3.htm. |
Web-Site Brochure dated Jan. 4, 2000. SOOIL-Homepage. “Portable Insulin Pump”. www.sooil.com/product4.htm. |
Web-Site Brochure dated Dec. 20, 1999. “The Animas R-1000 Insulin Pump”. www .animascorp.com/pump f _ s.html. |
Web-Site Brochure dated Dec. 20, 1999. ““The Animas R-1000 Insulin Pump””www.animascorp.com/pump_f_f.html. |
Web-Site Brochure dated Jan. 4, 2000. SOOIL-Homepage. “Ponable Insulin Pump”.www.sooil.com/intro2.htm. |
Web-Site Brochure dated Jan. 4, 2000. MiniMed 508. “Doing its job. Naturally.” www.minimed.com/tiles/mm 113.htm. |
Web-Site Brochure dated Dec. 20, 1999. Applied Medical Technology. “508 PumpInformation”. www.applied-medical.co.uk/508.htm. |
Web-Site Brochure dated Jan. 4, 2000. “The Glucose Sensor”.www.animascorp.corn/sensor f.html. |
Number | Date | Country | |
---|---|---|---|
20190374714 A1 | Dec 2019 | US |
Number | Date | Country | |
---|---|---|---|
62259706 | Nov 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15358945 | Nov 2016 | US |
Child | 16519349 | US |